Colon to Rectum

Gastroenterology. 2022;163(4):982–94.e14

El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG

Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation

Background and aims: The long-term efficacy and possible adverse events of fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS) are unknown. This study performed a 3-year follow-up of the patients in a previous clinical trial to clarify these aspects.
Methods: This study included 125 patients (104 females, and 21 males): 38 in a placebo group, 42 who received 30 g of donor feces, and 45 who received 60 g of donor feces. Feces was administered to the duodenum. The patients provided a fecal sample and completed 5 questionnaires at baseline and at 2 and 3 years after FMT. Fecal bacteria and dysbiosis index were analyzed using 16S ribosomal RNA gene polymerase chain reaction DNA amplification/probe hybridization covering the V3 to V9 regions.
Results: Response rates were 26.3%, 69.1%, and 77.8% in the placebo, 30-g, and 60-g groups, respectively, at 2 years after FMT, and 27.0%, 64.9%, and 71.8%, respectively, at 3 years after FMT. The response rates were significantly higher in the 30-g and 60-g groups than in the placebo group. Patients in the 30-g and 60-g groups had significantly fewer IBS symptoms and fatigue, and a greater quality of life both at 2 and 3 years after FMT. The dysbiosis index decreased only in the active treatment groups at 2 and 3 years after FMT. Fluorescent signals of 10 bacteria had significant correlations with IBS symptoms and fatigue after FMT in the 30-g and 60-g groups. No long-term adverse events were recorded.

Conclusions: Fecal microbiota transplantation performed according to the protocol resulted in high response rates and long-standing effects with only few mild self-limited adverse events.

Dr. Dr. M. El-Salhy, Section for Gastroenterology, Department of Medicine, Stord Helse Fonna Hospital, Stord, Norway,

DOI: DOI: 10.1053/j.gastro.2022.06.020

Back to overview

this could be of interest:

Effect of colonoscopy screening on risks of colorectal cancer and related death

N Engl J Med. 2022;387(17):1547–56

Fecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild-to-moderate ulcerative colitis: A randomized controlled trial

Gut. 2022;71(12):2401–13

More articles on the topic